Introduction. Young adults who inject drugs and live in rural communities are at high risk for hepatitis C virus (HCV) infection. Recent changes in HCV treatment
health promotion efforts (Centers for Disease Control and Prevention [CDC], 2017; Suryaprasad et al., 2014; Valdiserri et al., 2014; Zibbell et al., 2018) . Meanwhile, safe and effective medications for curing HCV have recently been approved (Vermehren, Park, Jacobson, & Zeuzem, 2018) . These exciting developments offer, for the first time, the opportunity to substantially affect the epidemic of HCV by curing the virus in large numbers of patients, including people who inject drugs.
In this new era of HCV treatment, public health initiatives are needed to dispel misconceptions about HCV in populations at high risk for infection. Frontline public health providers should be equipped with upto-date information about HCV in order to offer effective counseling in the field, particularly among young adults who inject drugs. In the ¡VÁLE! Hepatitis Treatment and Integrated Prevention Services study, we enrolled 183 young adult patients (44.3% women; 85.8% Latino/a) who inject drugs and reside in rural New Mexico between 2016 and 2018. We collected a series of frequently asked questions (FAQs) about HCV from study participants. Here, we offer these questions alongside up-to-date, evidence-based responses to each question that other providers and educators can apply in their own work.
> > rESEArcH SEttIng And MEtHodS

¡VÁLE! Field Environment and Study Recruitment
¡VÁLE! study staff traveled to two field enrollment sites in rural New Mexico in a mobile clinic van. The primary study site was located in Rio Arriba County (Figure 1 ) at the Santa Fe Mountain Center, which hosts a syringe services program and is colocated with other preventive, recovery, and treatment programs for persons who inject drugs. Study staff recruited potential participants with in-person engagement at the center, distributing written study information and answering questions in person. Staff at the Mountain Center did not directly recruit participants for the study but referred interested clients to study staff and placed study informational materials (e.g., flyers and study cards) in visible places at the center.
A secondary, short-term study site in Doña Ana County (Figure 1 ) was located at a clinic offering medication-assisted treatment for opioid use disorder and a drop-in center offering access to multiple services, including syringe exchange and case management. Similar engagement procedures were followed at this site. Flyers and study materials were posted at study sites and at locations (e.g., drop-in centers, local medical clinics, and community bulletin boards) that provided services to potential study participants. These materials included general information about the study, opportunities for free HCV testing, dates and times the study team would be present, and ways to contact study staff for more information.
¡VÁLE! Study Procedures
Eligible participants were 18 to 29 years old with self-reported injection drug use in the past 90 days. After providing consent, participants underwent screening for HCV using a rapid point-of-care antibody test (anti-HCV; OraSure© Technologies; Bethlehem, PA) and a blood test for HCV ribonucleic acid (RNA) to confirm active infection status, as well as screening for human immunodeficiency virus (HIV) and hepatitis B virus (sometimes abbreviated as HBV). For the purposes of this article describing work among youngadult patients, we have opted against the use of the HBV acronym, since it may be confused with another virus of clinical importance in this patient grouphuman papillomavirus or HPV.
All participants received counseling regarding infection prevention, referrals to local services, and resources for prevention, drug treatment, and behavioral health care. Participants were interviewed using a structured questionnaire about sociodemographic characteristics, risk exposures, injection drug use history, and selected health care utilization measures.
Participants were asked to return to the enrollment site to receive their HCV RNA results within 2 weeks. If HCV RNA test results were positive, indicating active HCV infection, participants underwent a oneon-one HCV education session and received a referral for HCV care. Participants were all asked to return for follow-up HCV testing and interviews every 3 months for 1 year.
FAQ Collection
¡VÁLE! study staff collected a series of FAQs about HCV that they encountered from study participants at various study visits, including visits for screening, laboratory test results, follow-up, and education sessions. These FAQs were organized into four categories: risk/prevention, screening, treatment, and reinfection. Responses to each question were developed using the best available professional literature as well as clinical and public health expertise in HCV prevention and management.
Ethics Approval
The University of New Mexico Institutional Review Board reviewed and approved the study, including all study procedures, data collection, HCV testing, and referrals to care. All FAQs are presented without identifiable details about study participants.
> > tooLS oF tHE trAdE: HcV FAQS
Characteristics of the overall ¡VÁLE! study population are shown in Table 1 . FAQs in each of the four domains are explored below.
Risk and Prevention
Participants expressed interest in assessing their own risk for infection as well as the risk of transmitting the virus to others in their families or social circles. In a number of instances, participants had previously been misinformed about how HCV is transmitted and prevented.
Q. How did I get HCV? Am I contagious? A. HCV is spread when the blood of a person with HCV comes into contact with the blood of a person who does not have HCV.
In the United States, it is most often spread through unsafe injecting practices, such as sharing contaminated injection equipment or other contaminated materials (e.g., syringes, cottons, cookers, and water). Less commonly, HCV may also be spread through sexual activity (most often in HIV-infected men who have sex with men), intranasal drug use (which may cause bleeding inside the nose), perinatal transmission from mother to fetus, nonsterile tattoo equipment, shared razors, and toothbrushes, or after other accidental blood contact.
HCV can survive outside the body on contaminated surfaces for days or weeks, if these surfaces are not properly sterilized. HCV can remain infectious in a syringe for as long as 2 months! Bleach disinfectants are much more effective than other household detergents/disinfectants (e.g., Dawn dish soap, Lysol cleaner), rubbing alcohol, or hydrogen peroxide. Rinsing syringes with water, beer, or wine is not effective in killing HCV.
The safest approach is never to share materials that may be contaminated with blood-such as needles, injection equipment, toothbrushes, razors, smoking devices, and intranasal devices. Ensure that all injection equipment is kept out of the reach of other household members, especially children, and dispose of all Some people's bodies clear HCV on their own (up to 25% of cases), and some others are cured of HCV after treatment. In these cases, where the virus has been cleared or cured, the confirmatory test will be negative.
If your confirmatory test is negative, the virus is not "dormant"; the virus is gone.
References: CDC (2013 CDC ( , 2018 Q. What is a "window period?"
A. The window period is the time after HCV exposure that it takes the body to produce enough antibodies to show up on a rapid screening test. This period usually lasts about 2 to 3 months. During the window period, it is possible to be infected without having a positive rapid-screening antibody test. Reference: CDC (2018) Q. How often should I be screened for HCV if I have risk factors for infection?
A. Yearly testing is recommended for all patients who inject drugs. More frequent screening may be considered if a new exposure is suspected, keeping in mind that the antibody screening test may not be positive until about 2 to 3 months after the new infection occurs (due to the window period described above). (2015) Q. If I had HCV while I was pregnant, should my child be tested?
Reference: American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD/IDSA) HCV Guidance Panel
A. Yes. Although the risk for mother-to-fetus transmission is low, your child should be tested. Treatment recommendations for children are likely to evolve and improve over the coming years, so determining your child's HCV status will help inform future decisions about starting treatment.
Reference: CDC (2018)
Treatment ¡VÁLE! participants expressed significant interest in HCV treatment, posing insightful questions about treatment risks and benefits as well as treatment availability for people in special circumstances (e.g., kidney problems). Often, participants reported not seeking treatment for their HCV infection due to certain behaviors or practices, such as current injection drug use.
However, HCV treatments, including those treatments available for patients who inject drugs, have changed substantially in the past 1 to 2 years.
Q. Can people cure themselves?
A. People with new HCV infections have a small chance-up to 25%-of clearing the infection on their own. For most people, however, the infection will not go away on its own; those people will have a chronic (longterm) infection and will need medication to cure it.
Reference: CDC (2018) Q. How is HCV treated? What are the side effects of treatment?
A. HCV treatments have changed a lot in recent years ( that they feel better immediately after treatment, even though they didn't notice feeling sick before. This is because HCV can cause other symptoms, such as fatigue and joint pain, which may improve after treatment. In our own clinical experience, some people also report feeling happier or more hopeful after their HCV is cured. 3. Benefits for others: Curing HCV can prevent spreading the virus to other people. 
Reinfection
Reinfection is of utmost concern for individuals who inject drugs. ¡VÁLE! study participants consistently inquired about whether HCV treatment conferred immunity and, if not, how to avoid reinfection during and after treatment.
Q. What is reinfection?
A. Reinfection is a new infection with HCV after a previous HCV infection was cleared spontaneously or cured with treatment. Patients who have cleared or cured the infection once are not immune from getting infected again.
There are 7 major types of HCV and more than 60 subtypes found in different places throughout the world. Infection with multiple types or subtypes-at one time or at different times-is possible. Thus, antibodies formed after infection with one subtype do not provide future immunity against HCV.
References: Blackard (2012); Smith et al. (2014) Q. Can I be reinfected during or after treatment?
A. Yes, you can be reinfected during or after treatment. However, diagnosis of reinfection can be tricky. A. It is important for everyone-including patients who are currently being treated for HCV or who have been treated for HCV in the past-to avoid potential exposures to the virus by following the recommendations in the "Risk and Prevention" section above.
Highlights and Resources for Frontline Providers
Frontline providers and health educators should be prepared to convey up-to-date information about HCV risk/prevention, screening, treatment, and reinfection to the communities they serve. The FAQs above may help providers anticipate and respond to questions from young adults in their communities.
Our study group plans to integrate these FAQs into our educational materials (e.g., using infographics or flash cards) for future fieldwork and to share what we have learned with other public health stakeholders in our community and region (e.g., using web-based postings or tools). Key points for providers and health educators to reinforce in patient education include the following:
1. Avoiding potential blood-to-blood exposures is the hallmark of preventing HCV infection and reinfection. Counseling should be reinforced at every possible opportunity (e.g., screening, treatment, or posttreatment evaluations and during visits to syringe services, sexually transmitted infection clinics, behavioral health support groups, or other public health interactions). Related resources for frontline providers: The FAQs provided here, along with those offered by national, state, or local public health entities may aid with the counseling process (CDC, 2016 (CDC, , 2018 . 2. HCV is now a curable condition, and treatment is recommended for patients who inject drugs. Treatments have become much more effective and much easier to tolerate compared with therapies used in years past (Table 2) . Currently, however, access to these medications varies from state to state. Related resources for frontline providers: The contrast between new and old treatments shown in School, 2018) . Providers are also encouraged to identify screening and treatment referral sites in their areas of practice to assist with patient counseling.
Although our study did not encounter specific questions about the use of herbs, supplements, or medical cannabis, such questions may be encountered by other frontline providers and clinicians. Providers may find the National Institutes of Health LiverTox database (https://livertox.nih.gov/) helpful to support discussions about the impacts of herbs, supplements, and medications on liver health.
> > concLuSIonS
Young adults who inject drugs and reside in rural areas of the United States are at high risk for HCV infection. The combination of operative prevention programs, including syringe services with effective counseling strategies employed by frontline providers, and access to safe, effective treatment regimens for affected patients could have a dramatic impact on this epidemic. As the questions posed in this study show, young adults often have important and insightful questions about HCV. Frontline providers should be prepared with equally important and insightful responses.
